TET2 and cancer: Similarly, exploring the molecular basis of TET2-associated immunodeficiency and TBRS, both of which are strongly linked to increased risk of hematopoietic malignancy, will help to elucidate the roles of TET2 and DNMT3A mutations as drivers of cancer.